Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

COMMENTED

Rheumatoid Arthritis

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

★ 2 Recommended and commented by Dr Heino Prillwitz, Faculty Member

Arthritis Res Ther.

Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B

doi: 10.1186/s13075-019-2020-x.

Rheumatoid Arthritis

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Ann Rheum Dis.

Sharma C, Whittle S, Haghighi PD, Burstein F, Sa'adon R, Keen HI

doi: 10.1136/annrheumdis-2020-217333.

Rheumatoid Arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Ann Rheum Dis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB

doi: 10.1136/annrheumdis-

PsoriasisRheumatoid Arthritis

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis

Semin Arthritis Rheum.

Baganz L, Listing J, Kekow J, Eisterhues C, Wassenberg S, Zink A, Strangfeld A

doi: 10.1016/j.semarthrit.2019.07.004.

Rheumatoid Arthritis

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Ann Rheum Dis.

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM

doi: 10.1136/annrheumdis-2020-217209.

Further Publications Rheumatology

Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study

Semin Arthritis Rheum

Dormuth CR, Fisher A, Hudson M, Austin PC, Ernst P, Bresee L, Chateau D, Tamim H, Paterson JM, Lafrance JP, Taylor-Gjevre RM, Platt RW, Canadian Network For Observational Drug Effect Studies Cnodes Investigators

doi: 10.1016/j.semarthrit.2021.08.002

Rheumatoid Arthritis

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

Ann Rheum Dis.

Kuijper TM, Luime JJ, de Jong PH, Gerards AH, van Zeben D, Tchetverikov I, de Sonnaville PB, van Krugten MV, Grillet BA, Hazes JM, Weel AE

doi: 10.1136/

Rheumatoid Arthritis

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

RMD Open.

Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M

doi: 10.1136/rmdopen-2016-000410.

Rheumatoid Arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

Ann Rheum Dis.

Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JW, Burmester GR, de Wit M, Falzon L, Landewé R

doi: 10.1136/annrheumdis-2019-216653.

Related content

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis